Studies have shown that immune checkpoint inhibitors, such as programmed death-1 antibodies, programmed death ligand-1 (PD-L1) antibodies, and (CTLA-4) antibodies, have demonstrated certain efficacy in the clinical treatment of HCC [4,44,45]. This evidence concerns the gene CD274 and hepatocellular carcinoma.